The Scale of Benefit and Cost Effectiveness of the Care Ecosystem for Alzheimer’s Disease relative to Lecanemab

Kelly J Atkins, James G Kahn, Katherine L Possin · 2025

Read The Scale of Benefit and Cost Effectiveness of the Care Ecosystem for Alzheimer’s Disease relative to Lecanemab by Kelly J Atkins, James G Kahn, Katherine L Possin (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715160.txt.

Description

Kelly Atkins, James Kahn, and Katherine Possin compare two paths for Alzheimer's care in a 2025 study: a new antibody drug and a team-based care program. The drug, lecanemab, slows the disease but fits only a small share of patients. The program, Care Ecosystem, gives patients and caregivers a navigator and expert backup, and it is open to far more people.

Using a decision model, the team found the drug added more healthy life per person, at a far higher cost. The care program added less per person but saved money compared with usual care. Scaled to the United States, the program reached millions more people and delivered far larger total gains while cutting costs. The drug's national bill, by contrast, ran to tens of billions. The authors urge policy to make team-based dementia care widely available.

Catalog record

CREATORKelly J Atkins, James G Kahn, Katherine L Possin
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11715160

Browse the full library · About the Tower of Babel